Maxcyte annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Maxcyte R&D Spending Growth & History (MXCT)
Maxcyte's r&d spending was $20.8M for fiscal 2025.
View full Maxcyte company overviewMaxcyte annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $20.8M | −$1.4M | −6.32% |
| 2024 | 2024-12-31 | $22.2M | −$1.6M | −6.68% |
| 2023 | 2023-12-31 | $23.8M | $4.3M | +22.05% |
| 2022 | 2022-12-31 | $19.5M | $4.1M | +26.65% |
| 2021 | 2021-12-31 | $15.4M | −$2.3M | −13.12% |
| 2020 | 2020-12-31 | $17.7M | $142,500 | +0.81% |
| 2019 | 2019-12-31 | $17.6M | — | — |
Maxcyte quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.3M | −$2.0M | −32.16% |
| Q1 2026 | 2026-03-31 | $3.9M | −$2.0M | −34.66% |
| Q4 2025 | 2025-12-31 | $3.3M | −$1.3M | −27.72% |
| Q3 2025 | 2025-09-30 | $5.3M | $0 | 0.00% |
| Q2 2025 | 2025-06-30 | $6.3M | $650,000 | +11.57% |
| Q1 2025 | 2025-03-31 | $5.9M | −$775,000 | −11.61% |
| Q4 2024 | 2024-12-31 | $4.6M | −$1.2M | −21.02% |
| Q3 2024 | 2024-09-30 | $5.3M | −$948,000 | −15.13% |
| Q2 2024 | 2024-06-30 | $5.6M | −$45,000 | −0.79% |
| Q1 2024 | 2024-03-31 | $6.7M | $631,000 | +10.43% |
| Q4 2023 | 2023-12-31 | $5.8M | $114,400 | +2.00% |
| Q3 2023 | 2023-09-30 | $6.3M | $938,900 | +17.63% |
| Q2 2023 | 2023-06-30 | $5.7M | $968,000 | +20.61% |
| Q1 2023 | 2023-03-31 | $6.0M | $2.3M | +60.60% |
| Q4 2022 | 2022-12-31 | $5.7M | $2.3M | +69.45% |
| Q3 2022 | 2022-09-30 | $5.3M | $2.6M | +93.86% |
| Q2 2022 | 2022-06-30 | $4.7M | $1.5M | +46.57% |
| Q1 2022 | 2022-03-31 | $3.8M | −$2.3M | −38.03% |
| Q4 2021 | 2021-12-31 | $3.4M | — | — |
| Q3 2021 | 2021-09-30 | $2.7M | −$1.8M | −39.20% |
| Q2 2021 | 2021-06-30 | $3.2M | −$886,500 | −21.67% |
| Q1 2021 | 2021-03-31 | $6.1M | — | — |
| Q3 2020 | 2020-09-30 | $4.5M | — | — |
| Q2 2020 | 2020-06-30 | $4.1M | — | — |
Maxcyte r&d spending trends
Over the last five fiscal years, Maxcyte's r&d spending increased from $17.7M to $20.8M, a change of $3.1M. The latest reported quarter, Q2 2026, shows $4.3M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Maxcyte source filings ↗